Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

1-s2.0-S0213005X21001907-main.pdf (809.07 KB)

Document type

Article

Version

Published version

Publication date

2022-12-01

Publication license

cc by (c) Pérez Elías, Maria Jesús et al., 2021
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/196116

Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.eimc.2021.05.006

Abstract

Introduction: Although antiretroviral therapy (ART) for HIV / AIDS was introduced in 1987, improvementin disease progression and reduction in mortality at a population level was not observed until 1996, withthe combination of three or more drugs. The objective was to estimate the clinical and economic benefitof ART in Spain in the 32-year period between 1987 and 2018. Methods: A cost-benefit analysis was performed, using a second-order Monte Carlo simulation, from the societal (base case) and the National Health System (NHS) perspectives. New cases of HIV, AIDS and related deaths were obtained from the SINIVIH and UNAIDS registries, with population projections without ART using triple exponential smoothing. Expenditure on ART was obtained from the National AIDS Plan reports and market studies. Results: The NHS invested 6,185 million euros in 32 years. In that period, 323,651 AIDS-related deaths, 500,129 AIDS cases and 161,417 HIV cases were averted, with total savings of 41,997 million euros. The net benefit (net savings) is estimated at 35,812 million euros (societal) and 1,032 million euros (NHS). For every euro invested in ART, a return on investment of (sic) 6.79 and (sic) 1.16 was obtained, respectively. Conclusion: The use of ART over 32 years prevented a large number of deaths and cases of AIDS and HIV, providing significant economic savings for the NHS. ART is an efficient intervention for the NHS. (c) 2021 The Author(s). Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica.

Subject

Antiretrovirals, Malalts de sida

Subject (English)

Antiretroviral agents, AIDS patients

Citation

Collections

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citation

PÉREZ ELÍAS, María Jesús, et al. Beneficio clínico y económico de 32 años de tratamiento antirretroviral de personas que viven con VIH en España: ¿ha sido una intervención eficiente?. Enfermedades Infecciosas y Microbiología Clínica. 2022. Vol. 40, num. 10, pags. 550-556. ISSN 1578-1852. [consulted: 16 of August of 2026]. Available at: https://hdl.handle.net/2445/196116

Export metadata

JSON - METS

Share record